SCHEMBL2391307

SCHEMBL2391307

NC(=O)Cc1cc(F)ccc1-c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 2/20 0.49
FFAR4 Q5NUL3 2/20 0.49
ICMT O60725 5/20 0.46
KCNA5 P22460 1/20 0.41
PTGS1 P23219 1/20 0.41
PPARG P37231 1/20 0.41
PTGDR2 Q9Y5Y4 1/20 0.41
MAPT P10636 1/20 0.40
MAP2 P11137 1/20 0.40
GRM2 Q14416 1/20 0.40
GRM5 P41594 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2393249 0.90 ICMT (0.45) FFAR1FFAR4ICMTPTGS1GRM2
SCHEMBL9890774 0.89 ICMT (0.54) FFAR1FFAR4ICMT
SCHEMBL2394999 0.87 ICMT (0.46) FFAR1FFAR4ICMTKCNA5PTGS1
SCHEMBL3731501 0.87 FFAR1 (0.54) FFAR1FFAR4PTGS1PPARGPTGDR2
SCHEMBL9890772 0.84 CYP2C19 (0.45) ICMT
SCHEMBL2395113 0.84 CHRM1 (0.45) ICMTPPARG
SCHEMBL2395238 0.83 ICMT (0.39) ICMTPPARGMAPTGRM2
SCHEMBL9890760 0.82 LMNA (0.46) ICMTPTGS1MAPTKMT2A
SCHEMBL9890776 0.82 PSEN1 (0.49) ICMTPPARG
SCHEMBL9890761 0.81 PTGDR2 (0.47) ICMTPTGS1PTGDR2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US claimed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP claimed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US claimed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 FFAR1 223/4885FFAR4 621/4885ICMT 2894/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 FFAR1 223/4885FFAR4 621/4885ICMT 2894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.